CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 178 enrolled
Drug / intervention
Relacorilant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03776812
NCT03776812Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Corcept Therapeutics·interventional·Posted Dec 17, 2018·Updated Oct 7, 2025

In Brief

A Phase 2 clinical trial evaluating Relacorilant and Nab-paclitaxel for Recurrent Ovarian Cancer and 2 related conditions. Completed, enrolled 178 participants across 24 sites in 5 countries.

Detailed Summary

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
CountriesBelgium, Canada, Italy, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 17, 2018
Enrollment StartApr 5, 2019
Primary CompletionMar 16, 2021
Study CompletionJul 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.5 years ago

Interventions

Relacorilantdrug

Relacorilant is supplied as capsules for oral dosing.

Nab-paclitaxeldrug

Nab-paclitaxel is administered as IV infusion over 30-40 minutes.